Effect of tween-20 on core biomarkers measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy control individuals

Journal of Alzheimer's Disease

Volumn 49, Issue 2, 2015, Pages 493-502

  Berge, Guro ^a   Lauridsen, Camilla ^a   Sando, Sigrid Botne ^a,b   Holder, Daniel Joseph ^c   Moller, Ina ^b   Aasly, Jan Olav ^a,b   Bråthen, Geir ^a,b   Savage, Mary Josephine ^c   White, Linda Rosemary ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amyloid beta peptides; dementia; human; synthetic detergent; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; DETERGENT; POLYSORBATE 20; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; POLYSORBATE; SURFACTANT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CEREBROSPINAL FLUID; DRUG EFFECTS; LONGITUDINAL STUDY; MIDDLE AGED; PHOSPHORYLATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POLYSORBATES; ROC CURVE; SURFACE-ACTIVE AGENTS; TAU PROTEINS;

EID: 84948669580     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150234     Document Type: Article

References (37)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
3. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13, 614-629.
4. Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
5. Hansson O, ZetterbergH, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimer's disease using the CSF A-42/A-40 ratio in patients with mild cognitive impairment. Dement Geriatric Cogn Disord 23, 316-320.
6. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, NowatzkeW, O'Brien R, Otto M, ParaskevasGP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395. e386.
7. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleo A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schroder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, BlennowK, KaserSA(2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261.
8. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, Umek R, Vandijck M, Salamone S, Bittner T, Shaw LM, Stephenson D, Bain L, Zetterberg H (2013) Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 9, 137-140.
9. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Saez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 6, 419-430.
10. Mattsson N, BlennowK, ZetterbergH(2010) Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: United we stand, divided we fall. Clin Chem Lab Med 48, 603-607.
11. Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, Dubois B (2014) Harmonized diagnostic criteria for Alzheimer's disease: Recommendations. J Intern Med 275, 204-213.
12. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, 986310.
13. Ferguson RE, Hochstrasser DF, Banks RE (2007) Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomics Clin Appl 1, 739-746.
14. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, ZorziW, Elmoualij B, Schraen S, Moreaud O, Gabelle A, Thouvenot E, Thomas-Anterion C, Touchon J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I, Lehmann S (2012) Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 31, 13-20.
15. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, BlennowK(2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73.
16. Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF (2010) Nonspecific binding of A-42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta 411, 1833.
17. Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, Dorey A, Dumurgier J, Hirtz C, Krolak-Salmon P, Laplanche JL, Moreaud O, Peoc'h K, Rouaud O, Sablonniere B, Thouvenot E, Touchon J, Vercruysse O, Hugon J, Gabelle A, Pasquier F, Perret-Liaudet A (2014) Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement 10(5 Suppl), S390-S394.e2.
18. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: Implications for use in clinical practice. Clin Chem 51, 189-195.
19. Le Bastard N, De Deyn PP, Engelborghs S (2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 61, 734-743.
20. Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME (2012) Development and advanced validation of an optimized method for the quantitation of A-42 in human cerebrospinal fluid. AAPS J 14, 510-518.
21. Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, Schott JM, Zetterberg H (2013) Identification of an important potential confound in CSF AD studies: Aliquot volume. Clin Chem Lab Med 51, 2311-2317.
22. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944.
24. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
25. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
26. Berge G, Sando SB, Rongve A, Aarsland D, White LR (2014) Apolipoprotein E-2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry 85, 1227-1231.
27. Hesse C, Larsson H, Fredman P, Minthon L, Andreason N, Davidsson P, Blennow K (2000) Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 25, 511-517.
28. Simonsen AH, Bahl JM, Danborg PB, Lindstrom V, Larsen SO, Grubb A, Heegaard NH, Waldemar G (2013) Preanalytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods 215, 234-240.
29. Team RDC (2011) R Foundation for Statistical Computing, Vienna, Austria.
30. Sprent P (1969) Models in Regression, ch. 3 Methuen & Co., London.
31. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M (2011) pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77.
32. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44, 837-845.
33. Izenman A (1991) Recent developments in nonparametric density estimation. J Am Statist Assoc 86, 205-224.
34. Altman N, Leger C (1995) Bandwidth selection for Kernel distribution function estimation. J Statist Planning Inference 46, 195-214.
35. Youden WJ (1950) Index for rating diagnostic tests. Cancer 3, 32-35.
36. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46, 235-240.
37. Mattsson N, Zetterberg H, Blennow K (2010) Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimer Dis 2010, 610613.